JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on CureVac (NASDAQ:CVAC) but lowers the price target from $18 to $16.

August 16, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on CureVac but lowers the price target from $18 to $16.
The Market Outperform rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100